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Abstract
Objective: Previous studies have suggested that C-reactive protein (CRP) was associated with risk of stroke. There were few
studies in Asian population, or on stroke subtypes other than ischemic stroke. We thus investigated the relationship
between CRP and the risks of all stroke and its subtypes in a Chinese adult population.
Methods: In the current study, we included 90,517 Chinese adults free of stroke and myocardial infarction at baseline (June
2006 to October 2007) in analyses. Strokes were classified as ischemic stroke (IS), intracranial heamorrhage (ICH) and
subarachnoid heamorrhage (SAH). High-sensitivity CRP (hs-CRP) were categorized into three groups: ,1 mg/L, 1 to 3 mg/L,
and .3 mg/L. Cox proportional hazards regression was used to calculate the association between hs-CRP concentrations
and all stroke, as well as its subtypes.
Results: During a median follow-up time of 49 months, we documented 1,472 incident stroke cases. Of which 1,049 (71.3%)
were IS, 383 (26.0%) were ICH, and 40 (2.7%) were SAH. After multivariate adjustment, hs-CRP concentrations $1 mg/L were
associated with increased risks of all stroke (hs-CRP 1–3 mg/L: hazard ratio (HR) 1.17, 95% confidential interval (CI) 1.03–1.33;
hs-CRP.3 mg/L: HR 1.25, 95% CI 1.07–1.46) and IS (hs-CRP 1–3 mg/L: HR 1.17, 95% CI 1.01–1.36; hs-CRP.3 mg/L: HR 1.33,
95% CI 1.11–1.60), but not with ICH and SAH. Subgroup analyses showed that higher hs-CRP concentration was more prone
to be a risk factor for all stroke and IS in non-fatal stroke, male and hypertensive participants.
Conclusion: We found that higher hs-CRP concentrations were associated with a higher risk of IS, particularly for non-fatal
stroke, male and hypertensive subjects. In contrast, we did not observe significant associations between hs-CRP and ICH/
SAH.
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Introduction
According to the Global Burden of Disease Study 2010, stroke
was the third leading cause of disability-adjusted life years
(DALYs) worldwide [1]. The same study showed that in China,
cardiovascular diseases (stroke and ischemic heart disease) were
the leading cause of DALYs, and stroke was the leading cause of
death [2]. Atherosclerosis is the most common cause of stroke. The
development of atherosclerosis was not only associated with
dyslipidemia [3], but also closely associated with inflammation.
The later was linked to the complexity and instability of plaques
[4]. C-reactive protein (CRP), an indicator of systemic inflamma-
tion, may predict the burden of atherosclerosis [5,6].
Although many studies showed that CRP was associated with
increased risk of stroke [7–10], others did not find the significant
association [11,12]. Most of these studies with positive findings
focused on ischemic stroke. In addition, most of these studies were
in Europe and America with majority of non-Asian population. It
has been shown that Asians tend to have higher concentrations of
CRP than European whites [13]. To our knowledge there is no
large scale study on CRP as a risk factor of stroke or its subtypes in
Chinese. We therefore conducted a large prospective study to
investigate the relationship between CRP concentrations and
stroke and its subtypes, i.e. ischemic stroke (IS), hemorrhagic
stroke (ICH) and subarachnoid heamorrhage (SAH) using samples
from Kailuan Study.
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Study Design and Population
The Kailuan study was a longitudinal, ongoing community
health study based on Kailuan community in Tangshan city,
which is a large and littoral modern city located in the southeast of
Beijing. From June 2006 to October 2007, all employees
(including the retired) in the community (155,418) were invited
to participate the study, and 65.3% of them agreed. After
screening against the inclusion criteria (1) aged 18 years or older;
(2) providing written informed consent; and (3) updating their
health status every year and biennial measurements of the below
parameters according to the follow-up protocol, 101,510 partic-
ipants (81,110 men and 20,400 women, aged 18–98 years old)
were recruited into the Kailuan study. All participants underwent
a questionnaire survey, clinical examination, and laboratory
testing, which were conducted in the 11 hospitals in Kailuan
community, following standard protocols described previously
[14].
In this study, we excluded subjects who had a history of
myocardial infarction (MI) (1,112), stroke (2,355), or both (203) at
baseline. Because hs-CRP concentrations .10.0 mg/L suggesting
an acute inflammation, we also excluded participants with hs-CRP
concentrations .10.0 mg/L (7,323), leaving 90,517 subjects
included in the analyses. This study was performed according to
the guidelines of Helsinki Declaration and was approved by the
Ethics Committees of Kailuan General Hospital, Beijing
Chaoyang Hospital and Beijing Tiantan Hospital, as a collabo-
rative project.
Assessment of Stroke and stroke subtypes
The primary outcome was the first incidence of stroke, either
nonfatal or fatal. The diagnosis of stroke was made according to
World Health Organization (WHO) criteria [15] confirmed with
brain computed tomography (CT) or magnetic resonance (MR),
and classified into one of the three subtypes: IS, ICH, or SAH,
following unified protocol. A nonfatal stroke was defined as a focal
neurological deficit of sudden onset and vascular mechanism that
lasted .24 hours. Fatal stroke were the deaths caused by a
confirmed cerebrovascular mechanism.
The stroke history of all participants was recorded biennially at
clinic visits or telephone interviews from the baseline survey
through December 31, 2010, or to the date of death or loss to
follow-up. The results were confirmed by hospital discharge
summaries or death certificates.
Assessment of Variables
Information on demographic variables (e.g. age, sex), smoking
and alcohol habit, and past medical history were collected via
questionnaires administered by the research doctors at the baseline
interview. Hypertension was defined by the presence of any of the
following: a history of hypertension, using antihypertensive
treatment, a systolic blood pressure $140 mmHg, or a diastolic
pressure $90 mmHg. Diabetes mellitus was diagnosed by the
presence of any of the following: a history of diabetes mellitus,
currently treated with insulin or oral hypoglycemic agents, or the
fasting blood glucose level was $7.0 mmol/L. Hyperlipidemia
was defined by the presence of any of the following: a history of
hyperlipidemia, current use of cholesterol lowering agents, or the
total cholesterol level $5.17 mmol/L or triglyceride $1.7 mmol/
L.
Body weight, height and blood pressure (Bp) were measured
during the baseline interview, and body mass index (BMI) was
calculated. Bp was the average of at least two readings at rest.
Blood samples were obtained after an overnight fast in EDTA
tubes at the baseline interview. Fasting blood glucose was
measured with the hexokinase/glucose-6-phosphate dehydroge-
nase method. Cholesterol and triglyceride were measured enzy-
matically (Mind Bioengineering Co. Ltd, Shanghai, China). High-
sensitivity (Hs)-CRP was measured by high-sensitivity nephelom-
etry assay (Cias Latex CRP-H, Kanto Chemical Co. Inc, Tokyo,
Japan). All blood variables were measured using an auto-analyzer
(Hitachi 747; Hitachi, Tokyo, Japan) at the central laboratory of
the Kailuan General Hospital. According to the guideline from the
centers for Disease Control and Prevention and the American
Heart Association, hs-CRP concentrations were categorized into
three groups: hs-CRP,1 mg/L, hs-CRP 1 to 3 mg/L, and hs-
CRP.3 mg/L [16].
Statistical Analysis
Statistical analyses were performed using SAS software, version
9.1 (SAS Institute, Cary, North Carolina, USA). As all the
continuous variables were in skewed distribution, median were
used for analysis, and compared using analysis of variance
(ANOVA). Hs-CRP was log-transformed as a continuous variable
to fit a less skewed distribution. Categorical variables were
described by percentages, and compared using Chi-Square tests.
Direct standardization method was used to calculate the age- and
sex-standardized incidence rates according the National popula-
tion census in 2010. Hazard ratios (HRs) and 95% confidence
intervals (CI) of stroke and its subtypes were estimated according
to different hs-CRP concentrations and 1-SD increment of log-
transformed hs-CRP (antilog of SD=3.0 mg/L) with Cox
proportional hazards regression models [17]. Adjustment was
made for age, sex, hypertension, diabetes, dyslipidemia and for
SBP, DBP, BMI, TC, TG, LDL, GLU, current smoking, alcohol
intake, and antihypertensive treatment, lipid-lowering treatment,
hypoglycemic treatment were also conducted. The Kaplan-Meier
curves for cumulative stroke and its subtypes were plotted
according to hs-CRP concentrations and compared with the log-
rank test. Receiver Operating Characteristic (ROC) analysis was
used to determinate the cut-off-points of hs-CRP concentrations
for the prediction of all stroke and stroke subtypes, as well as their
predicted efficiency. All statistical tests were 2-sided, and the
significant level was set at 0.05.
Results
Baseline characteristics according to hs-CRP concentrations
were presented in Table 1. Male subjects were in higher
proportion (79.5%) in the study. Subjects in the groups of higher
hs-CRP concentrations ($1 mg/L) were older. High hs-CRP
concentrations ($1 mg/L) were associated with higher prevalence
of traditional stroke risk factors, including hypertension (both
systolic and diastolic), diabetes, dyslipidemia, high BMI, and
elevated concentrations of fasting glucose, total cholesterol (TC),
triglycerides (TG) and low-density lipoprotein cholesterol (LDL).
Interestingly, of the three groups, the concentrations of TC, TG,
LDL and the prevalence of dyslipidemia, current smoking/alcohol
intake, and taking antihypertensive/hypoglycemic drug therapy
were the highest in the hs-CRP of 1 to 3 mg/L group.
The total follow-up time was 362,163 person-years, with a
median follow-up time of 49 months per participants. At the end
of the study, we identified 1,472 new stroke cases, of which 1,049
(71.3%) were IS, 383 (26.0%) were ICH, and 40 (2.7%) were
SAH. The age- and sex-standardized incidence per 1000 person-
years of all stroke and stroke subtypes in this cohort according to
CRP Concentrations Were Associated with Ischemic Stroke
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rates of IS and ICH increased with hs-CRP concentrations.
Table 3 showed the hazard rations (HR) of all stroke and its
subtypes according to serum hs-CRP concentrations using Cox
proportional hazards models. In unadjusted models, elevated hs-
CRP concentrations were associated with significant high risk of
all stroke, IS and ICH, respectively. Adjusting for age and sex did
not attenuate the trend in all stroke and IS in both groups of
elevated hs-CRP groups ($1 mg/L). After multivariate adjust-
ment, elevated hs-CRP concentrations ($1 mg/L) showed persis-
tent association with increased risk of all stroke and IS. However,
elevated hs-CRP ($1 mg/L) was not significantly associated with
the risk of ICH after adjusting for age and sex and multivariate
adjustment (Table 3). There was no significant association
between hs-CRP concentrations and the risk of SAH.
To further explore the effects of hs-CRP on the outcome of
stroke, and sex difference, subgroup analyses were conducted in
fatal/non-fatal stroke, male/female and participants with/without
hypertension (Table 4). It showed that elevated hs-CRP was a risk
factor for non-fatal all stroke, and non-fatal IS. Elevated hs-CRP
had significant effect on male subjects in all stroke and IS. Elevated
hs-CRP was not associated with fatal stroke, and had no significant
effect on female.
Because hypertension is an independent risk factor for
heamorrhagic stroke, to further explore the potential association
between hs-CRP and heamorrhagic stroke, subgroup analysis was
carried out based on hypertension status (yes/no) (Table 4). Hs-
Table 1. Baseline characteristics according the hs-CRP groups.
hs-CRP
Total ,1 mg/L 1–3 mg/L .3 mg/L P value
Number 90517 52388(57.9) 23547(26.0) 14582(16.1)
Age, year 51.4(43.3–58.4) 50.1(42.4–56.6) 52.1(43.7–59.4) 54.9(48.3–63.2) ,0.001
Male, n(%) 71967(79.5) 42019(80.2) 18723(79.5) 11225(77.0) ,0.001
SBP (mmHg) 129.7(118.7–140.7) 126.0(115.3–140.0) 130.0(120.0–146.0) 130.0(120.0–149.3) ,0.001
DBP (mmHg) 80.0(78.7–90.0) 80.0(76.7–90.0) 80.7(79.3–90.0) 80.7(79.3–90.0) ,0.001
Hypertention, n(%) 38943(43.5) 20394(39.0) 11173(47.6) 7376(53.1) ,0.001
BMI, kg/m
2 24.8(22.6–27.2) 24.4(22.2–26.6) 25.6(23.4–27.9) 25.4(23.1–27.8) ,0.001
TC, mmol/L 4.9(4.3–5.6) 4.9(4.3–5.5) 5.0(4.3–5.7) 4.9(4.3–5.6) ,0.001
TG, mmol/L 1.3(0.9–1.9) 1.2(0.9–1.8) 1.4(1.0–2.1) 1.4(1.0–2.1) ,0.001
HDL, mmol/L 1.5(1.3–1.8) 1.5(1.3–1.8) 1.5(1.3–1.7) 1.5(1.3–1.8) ,0.001
LDL, mmol/L 2.4(1.8–2.8) 2.4(1.9–2.8) 2.4(1.9–2.9) 2.2(1.3–2.8) ,0.001
hs-CRP, mg/L 0.7(0.3–1.9) 0.3(0.2–0.6) 1.6(1.2–2.1) 5.2(3.8–7.2) ,0.001
Dislipidemia, n(%) 31237(34.5) 16518(31.5) 9100(38.7) 5619(38.5) ,0.001
GLU, mmol/L 5.1(4.7–5.7) 5.1(4.7–5.6) 5.2(4.7–5.9) 5.1(4.6–5.8) ,0.001
Diabetes, n(%) 8055(9.1) 3707(7.1) 2596(11.1) 1752(13.2) ,0.001
Current smoker, n(%) 30621(34.5) 18249(34.9) 8371(35.7) 4001(30.3) ,0.001
Alcohol intake, n(%) 33372(37.5) 20093(38.6) 9052(38.6) 4227(32.0) ,0.001
Antihypertensive treatment, n(%) 8916(9.9) 3931(7.5) 3128(13.3) 1857(12.7) ,0.001
Lipid-lowering treatment, n(%) 667(0.7) 295(0.6) 221(0.9) 151(1.0) ,0.001
Hypoglycemic treatment, n(%) 1914(2.1) 874(1.7) 663(2.8) 377(2.6) ,0.001
BMI: body mass index; DBP: diastolic blood pressure; GLU: glucose; HDL: high density lipoprotein; hs-CRP: high-sensitivity C-reactive protein; LDL: low density
lipoprotein; SBP: systolic blood pressure; TC: total cholesterol; TG: triglyceride.
Age, SBP, DBP, BMI, TC, TG, HDL, LDL, hs-CRP and GLU are shown in median (lower quartile, upper quartile). Numbers of each group, Male, Hypertension, Dislipidaemia,
Diabetes, Current smoker, Alcohol intake, antihypertensive treatment, lipid-lowering treatment and hypoglycemic treatment are shown in number (percentage).
doi:10.1371/journal.pone.0107017.t001
Table 2. The age- and sex-standardized incidence per 1000 person-years of stroke subtypes according to hs-CRP concentrations.
hs-CRP
,1 mg/L 1–3 mg/L .3 mg/L P trend
All stroke 9.89 13.95 18.49 ,0.01
IS 6.51 9.52 13.24 ,0.01
ICH 3.04 4.36 4.61 0.04
SAH 0.33 0.68 0.64 0.17
hs-CRP: high-sensitivity C-reactive protein; ICH: intracranial heamorrhage; IS: ischemic stroke; SAH: subarachnoid heamorrhage.
doi:10.1371/journal.pone.0107017.t002
CRP Concentrations Were Associated with Ischemic Stroke
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with hypertension, but in participants without hypertension, only
hs-CRP.3 mg/L was a risk factor for all stroke and IS. Elevated
hs-CRP concentrations again were not associated with the risk of
ICH and SAH, regardless of hypertension status.
The Kaplan-Meier plot of stroke and stroke subtypes according
to the concentrations of hs-CRP showed the cumulative incidence
rates of all stroke, IS and ICH were associated with elevated hs-
CRP concentrations, but not with SAH (Figure 1). Further ROC
analysis showed the cut-off-points of hs-CRP concentrations for all
stroke, IS and ICH were 1.34 mg/L, 1.01 mg/L and 0.84 mg/L,
respectively, and the areas under ROC curve were 0.592, 0.611
and 0.537, correspondingly.
Discussion
Previous studies showed that CRP concentrations were mod-
estly associated with the risk of IS [8,10,18] and transient ischemic
attack (TIA) [10] in middle-aged [18] and elderly individuals
[8,10]. Most of these were American studies, and focused on IS. In
a Japanese retrospective study, elevated CRP concentrations were
associated with higher incidence of all stroke and IS, but not
heamorrhagic stroke [17]. There was also a study showed high
CRP level was a strong risk factor for fatal stroke [19]. Based on
these studies, we conducted this community based, prospective
study to explore the relationship between CRP concentrations and
the incidence of stroke and its subtypes in Chinese. In this large
study of 90,517 Chinese, we confirmed that elevated hs-CRP
concentrations were significantly associated with increased risk of
all stroke and IS, but not ICH and SAH. The higher hs-CRP
concentrations, the higher incidence rates of all stroke, IS and
ICH, but not that of SAH.
The pathophysiological mechanism of the association between
elevated CRP concentrations and the risk of stroke is yet fully
elucidated. CRP is an indicator of inflammation, both acute and
chronic systemic inflammation [20]. Inflammation may promote
thrombosis and vascular injury, which are responsible for most
cardiovascular diseases [21]. Studies suggested that inflammation
may affect the composition, morphology and stability of athero-
sclerotic plaque [4,5]. An autopsy study demonstrated the
existence of CRP in the atherosclerotic coronary arteries but not
in the normal ones; and the intensity of CRP staining was
correlated with the relative intimal thickness [22]. CRP may also
promote thrombotic events by inducing monocytes to express
tissue factor, a potent procoagulant [23]. Because large-artery
atherosclerosis is the most common cause of IS [24], our clinical
findings are in line with those studies [7–10,17–19], showing that
the elevated CRP concentrations are associated with increased risk
of IS.
Research on the relationship between CRP and ICH was
scarce, with limited data suggesting that CRP concentrations are
not associated with ICH [17,25,26]. However, this study
demonstrated, at least a trend, that with the increase of hs-CRP
concentrations, the incidence of ICH increased. There were
studies showed that CRP concentrations were associated with
white matter lesions, suggesting inflammatory process involvement
in the pathogenesis of cerebral small vessel disease [27]. It is
known that ICH can be due to the rupture of small vessels from
lipohyalinosis secondary to hypertension [28], or by amyloid
angiopathy [29]. The relationship between CRP and ICH was
Table 3. Hazard ratios (HR) and 95% confidence intervals (95% CI) of all stroke and stroke subtypes according to serum hs-CRP
concentrations.
hs-CRP
,1 mg/L 1–3 mg/L .3 mg/L 1SD increment of log hs-CRP
All stroke N(%) 652(1.24) 440(1.87) 380(2.61)
Crude Model 1.00(Reference) 1.50(1.33–1.69)** 1.80(1.56–2.09)** 1.32(1.24–1.40)**
Model 1 1.00(Reference) 1.32(1.17–1.49)** 1.45(1.24–1.68)** 1.18(1.11–1.26)**
Model 2 1.00(Reference) 1.17(1.03–1.33)* 1.25(1.07–1.46)* 1.09(1.02–1.16)*
IS N(%) 442(0.84) 315(1.34) 292(2.00)
Crude Model 1.00(Reference) 1.55(1.34–1.80)** 1.99(1.67–2.37)** 1.42(1.32–1.53)**
Model 1 1.00(Reference) 1.35(1.17–1.56)** 1.58(1.32–1.88)** 1.26(1.17–1.36)**
Model 2 1.00(Reference) 1.17(1.01–1.36)* 1.33(1.11–1.60)* 1.15(1.06–1.24)**
ICH N(%) 192(0.37) 111(0.47) 80(0.55)
Crude Model 1.00(Reference) 1.35(1.07–1.71)* 1.43(1.05–1.93)* 1.11(0.99–1.24)
Model 1 1.00(Reference) 1.22(0.96–1.55) 1.18(0.86–1.61) 1.02(0.91–1.14)
Model 2 1.00(Reference) 1.15(0.90–1.47) 1.09(0.79–1.50) 0.97(0.86–1.08)
SAH N(%) 18(0.03) 14(0.06) 8(0.05)
Crude Model 1.00(Reference) 1.57(0.78–3.19) 0.96(0.33–2.79) 1.32(0.90–1.93)
Model 1 1.00(Reference) 1.49(0.73–3.04) 0.87(0.30–2.59) 1.27(0.86–1.87)
Model 2 1.00(Reference) 1.29(0.63–2.65) 0.69(0.22–2.15) 1.14(0.76–1.70)
*P,0.05,
**P,0.001.
hs-CRP: high-sensitivity C-reactive protein; ICH: intracranial heamorrhage; IS: ischemic stroke; SAH: subarachnoid heamorrhage.
Model 1: adjusted for age and sex.
Model 2: adjusted for Model 1 and for hypertension, diabetes, dyslipidemia and for SBP, DBP, BMI, TC, TG, LDL, GLU, current smoking, alcohol intake, antihypertensive
treatment, lipid-lowering treatment and hypoglycemic treatment.
doi:10.1371/journal.pone.0107017.t003
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were associated with cerebral microbleeds, in both lobar and deep
locations [30]. Cerebral microbleeds were strongly associated with
the occurrence of ICH [31]. Thus, the finding in our study was not
completely unexpected, although the results from multivariant
adjustment suggesting elevated hs-CRP may not be an indepen-
dent risk factor for ICH, or it may be only associated with certain
subtype of ICH that associated with inflammation. This is in
agreement with previous studies.
The results of the relationship between hs-CRP and SAH were
similar to previous studies [26,32] in which hs-CRP concentrations
were not associated with the SAH risk. This might be due to the
main risk factors for SAH are current smoking, hypertension and
alcohol intake [33], and atherosclerosis plays a weak role in
intracranial aneurysm [34]. It might also be possible that the
incidence of SAH is very low, nearly 10.5 per 100,000 person
years [35], which made this study under-powered to detect the
significance.
The current study is a large-scale community based study, with
a good number of incident stroke cases. There are also some
methodological strengths, such as prospective design, and detailed
follow-up and data collection. However, this study had some
limitations. First, during the follow-up, some participants might
start or withdraw lipid-lowering treatment, which might affect
Table 4. Subgroup Analysis of hazard ratios (HR) and 95% confidence intervals (95% CI) of all stroke and stroke subtypes
according to serum hs-CRP concentrations.
hs-CRP
,1 mg/L 1–3 mg/L .3 mg/L HR for 1SD increment of log hs-CRP
Fatal stroke All/IS/ICH/SAH, n 59/30/24/5 36/23/12/1 36/27/8/1
All stroke Model 2 1.00(Reference) 1.08(0.71–1.66) 1.17(0.69–1.97) 1.13(0.91–1.39)
IS Model 2 1.00(Reference) 1.32(0.75–2.30) 1.68(0.89–3.17) 1.38(0.99–1.80)
ICH Model 2 1.00(Reference) 0.97(0.48–1.99) 0.72(0.25–2.02) 0.92(0.66–1.28)
SAH Model 2 1.00(Reference) 0.24(0.03–2.27) 0.12(0.00–3.50) 0.63(0.27–1.48)
Non-fatal stroke All/IS/ICH/SAH, n 593/412/168/13 404/292/99/13 344/265/72/7
All stroke Model 2 1.00(Reference) 1.18(1.04–1.35)* 1.26(1.07–1.48)* 1.09(1.02–1.16)*
IS Model 2 1.00(Reference) 1.16(1.00–1.36) 1.31(1.08–1.58)* 1.13(1.04–.23)*
ICH Model 2 1.00(Reference) 1.18(0.91–1.53) 1.15(0.82–1.61) 0.98(0.87–1.10)
SAH Model 2 1.00(Reference) 1.77(0.80–3.90) 0.97(0.29–3.25) 1.31(0.84–2.06)
Male All/IS/ICH/SAH, n 588/402/171/15 387/281/96/10 326/257/64/5
All stroke Model 2 1.00(Reference) 1.15(1.01–1.31)* 1.25(1.06–1.48)* 1.09(1.02–1.17)*
IS Model 2 1.00(Reference) 1.16(0.99–1.36) 1.37(1.13–1.66)* 1.07(1.04–1.11)*
ICH Model 2 1.00(Reference) 1.13(0.87–1.46) 1.00(0.70–1.43) 1.01(0.96–1.17)
SAH Model 2 1.00(Reference) 1.10(0.48–2.49) 0.58(0.15–2.23) 0.97(0.76–1.18)
Female All/IS/ICH/SAH, n 64/40/21/3 53/34/15/4 54/35/16/3
All stroke Model 2 1.00(Reference) 1.36(0.93–2.00) 1.29(0.81–2.04) 1.06(0.88–1.29)
IS Model 2 1.00(Reference) 1.29(0.79–2.10) 1.11(0.61–2.00) 1.08(0.84–1.32)
ICH Model 2 1.00(Reference) 1.35(0.68–2.68) 1.66(0.76–3.63) 1.03(0.86–1.21)
SAH Model 2 1.00(Reference) 2.51(0.53–12.03) 1.11(0.11–11.08) 1.08(0.76–1.40)
Hypertension All/IS/ICH/SAH, n 444/303/133/8 338/241/86/11 277/208/62/7
All stroke Model 3 1.00(Reference) 1.19(1.03–1.38)* 1.29(1.09–1.52)* 1.11(1.03–1.19)*
IS Model 3 1.00(Reference) 1.20(1.01–1.43)* 1.37(1.13–1.66)* 1.16(1.06–1.26)**
ICH Model 3 1.00(Reference) 1.10(0.84–1.46) 1.06(0.76–1.47) 0.96(0.85–1.09)
SAH Model 3 1.00(Reference) 2.23(0.89–5.61) 1.67(0.53–5.26) 1.62(0.98–2.68)
Non-hypertension All/IS/ICH/SAH, n 208/139/59/10 102/74/25/3 103/84/18/1
All stroke Model 3 1.00(Reference) 1.11(0.87–1.42) 1.49(1.15–1.94)* 1.20(1.08–1.34)**
IS Model 3 1.00(Reference) 1.15(0.86–1.53) 1.69(1.25–2.28)** 1.34(1.17–1.54)**
ICH Model 3 1.00(Reference) 1.11(0.69–1.78) 1.14(0.65–1.98) 0.96(0.79–1.17)
SAH Model 3 1.00(Reference) 0.72(0.19–2.65) 0.41(0.05–3.31) 0.93(0.54–1.59)
*P,0.05,
**P,0.001.
hs-CRP: high-sensitivity C-reactive protein; ICH: intracranial heamorrhage; IS: ischemic stroke; SAH: subarachnoid heamorrhage.
Model 1: adjusted for age and sex.
Model 2: adjusted for Model 1 and for hypertension, diabetes, dyslipidemia and for SBP, DBP, BMI, TC, TG, LDL, GLU, current smoking, alcohol intake, antihypertensive
treatment, lipid-lowering treatment and hypoglycemic treatment.
Model 3: adjusted for Model 1 and for diabetes, dyslipidemia and for SBP, DBP, BMI, TC, TG, LDL, GLU, current smoking, alcohol intake, antihypertensive treatment, lipid-
lowering treatment and hypoglycemic treatment.
doi:10.1371/journal.pone.0107017.t004
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adjust for these factors. However, at the baseline, only ,1%
participants took lipid-lowering medicine in this cohort, and even
fewer participants changed medicine during the study. Thus the
impact of the usage of lipid-lowering agents on the results can be
neglected. Second, because of the industrial nature of Kailuan
Community, there was an imbalance in gender distribution, more
men than women. However, the incidence rates of stroke subtypes
were similar in Chinese men and women [37], thus the influence
of imbalance in gender distribution on the results would be
minimal.
Conclusion
We observed that elevated hs-CRP concentrations were
positively associated with the risk of ischemic stroke, particularly
for non-fatal stroke, male and hypertensive subjects, but not of
Figure 1. Kaplan-Meier plot for cumulative stroke and stroke subtypes according to hs-CRP concentration concentrations. hs-CRP:
high-sensitivity C-reactive protein; ICH: intracranial heamorrhage; IS: ischemic stroke; SAH: subarachnoid heamorrhage. The cumulative incidence rate
of all stroke, IS and ICH increased with increased concentrations of hs-CRP. There was no significant difference in the incidence of SAH in each hs-CRP
groups.
doi:10.1371/journal.pone.0107017.g001
CRP Concentrations Were Associated with Ischemic Stroke
PLOS ONE | www.plosone.org 6 September 2014 | Volume 9 | Issue 9 | e107017intracranial hemorrhage and subarachnoid heamorrhage. Based
on this large population study, CRP concentrations can be used as
a clinical screen tool to identify individuals with higher risk of
ischemic stroke in Chinese population.
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